Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma

R. LeBlanc, K. Song, D. White, A. Christofides, S. Doucette


The 2019 annual meetings of the American Society of Clinical Oncology and the European Hematology Association took place, respectively, in Chicago, Illinois, 31 May–4 June, and in Amsterdam, Netherlands, 13–16 June. At the meetings, results from key studies on the treatment of patients with relapsed or refractory multiple myeloma with high-risk cytogenetics were presented. Our meeting report describes those studies and includes interviews with investigators and commentaries by Canadian hematologists about the potential impact on Canadian practice.


Relapsed disease; refractory disease; multiple myeloma; high-risk cytogenetics

Full Text:


DOI: http://dx.doi.org/10.3747/co.26.5565

Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)